MSFinals-1826

A 52-year-old female visits her GP complaining of hot flashes, irritability, and a 7-month history of lighter periods that have become more irregular. The GP diagnoses her as perimenopausal and prescribes Elleste duet tablets (estradiol + norethisterone) as sequential combined HRT since she has not had a total abdominal hysterectomy. The GP discusses the potential risks with the patient. What is the most crucial risk to mention regarding the norethisterone component?